Skip to main content
Health & Medicine

Cangrelor versus crushed ticagrelor in acute myocardial infarction complicated by cardiogenic shock (DAPT-SHOCK-AMI): a randomised, double-blind trial.

| Source: Lancet (London, England)

Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) can compromise the administration and absorption of oral P2Y 12 inhibitors and carries high ischaemic and mortality risks. This trial assessed whether intravenous cangrelor was non-inferior to crushed oral ticagrelor for short-term clinical outcomes and whether it provided faster and more consistent platelet inhibition in patients with AMI-CS. DAPT-SHOCK-AMI was a double-blind trial conducted at 29 hospitals across five Europe

Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) can compromise the administration and absorption of oral P2Y 12 inhibitors and carries high ischaemic and mortality risks. This trial assessed whether intravenous cangrelor was non-inferior to crushed oral ticagrelor for short-term clinical outcomes and whether it provided faster and more consistent platelet inhibition in patients with AMI-CS. DAPT-SHOCK-AMI was a double-blind trial conducted at 29 hospitals across five European countries (Czech Republic, France, Germany, Poland, and Slovakia). Patients older than 18 years with AMI-CS were randomly assigned (1:1 ratio, stratified by centre, age, sex, presence or absence of ST-segment elevation, and mechanical ventilation) to cangrelor (30 μg/kg bolus followed by an infusion of 4 μg/kg per min for at least 2 h) or crushed ticagrelor (180 mg loading dose). The primary laboratory endpoint was a platelet reactivity index of less than 50% at the end of primary percutaneous coronary intervention. The primary clinical endpoint was death, myocardial infarction, or ischaemic stroke at 30 days. The primary clinical endpoint was analysed for non-inferiority with a prespecified margin of 1 percentage point among all randomly assigned patients who received study treatment. The study is registered with ClinicalTrials.gov (NCT03551964) and EudraCT (2018-002161-19); recruitment and 1-year follow-up are complete, and 5-year follow-up is ongoing. Between Aug 1, 2018, and Jan 19, 2024, 605 patients (137 [23%] were female) were randomly assigned to cangrelor (n=298) or ticagrelor (n=307); no surviving patients were lost to the 1-year follow-up. The primary laboratory endpoint was analysed in 56 (19%) patients in the cangrelor group and 68 (22%) in the ticagrelor group, and was achieved in 56 (100%) of 56 patients receiving cangrelor and 15 (22%) of 68 receiving ticagrelor (p<0·0001). The 30-day primary clinical endpoint occurred in 112 (38%) of 298 patients receiving cangrelor and 126 (41%) of 307 receiving ticagrelor; non-inferiority was not demonstrated (difference -4 percentage points [90% CI -10 to 3]; P non-inferiority =0·13). Major bleeding at 30 days occurred in 19 (6%) of 298 patients receiving cangrelor and 16 (5%) of 307 receiving ticagrelor. To our knowledge, this is the first randomised trial to compare P2Y 12 inhibitor strategies specifically in patients with AMI-CS. Cangrelor achieved effective platelet inhibition more frequently than crushed ticagrelor at the end of primary percutaneous coronary intervention. Non-inferiority of cangrelor versus crushed ticagrelor was not demonstrated for the primary 30-day clinical endpoint. These trial findings can inform future trials of P2Y 12 inhibition strategies in patients with AMI-CS. Czech Republic Ministry of Health, Charles University (Czech Republic), and NextGenerationEU.

Read the original source →

Related Stories

Health & Medicine

Homeostatic control of stem cell activity during intestinal regeneration.

Stem cells proliferate rapidly to maintain tissue turnover during regeneration, yet the mechanisms preventing hyperproliferation remain unclear. Here, we identified nuclear factor Y (NF-Y) as a transcriptional repressor that maintains intestinal stem cell (ISC) quiescence. NF-Y restricts ISC proliferation by occupying the promoters of epidermal growth factor receptor (EGFR) signaling components, including Egfr , Mkp3 , Raf , Ras , and pnt , through regulation dependent on the histone acetyltrans

Continue reading
Health & Medicine

Spatial transcriptomics reveals organizational properties of the mouse spinal cord and alterations in neuropathic pain.

The spinal cord integrates diverse somatosensory inputs and executes motor outputs through anatomically and functionally distinct circuits. Here, we employed spatially resolved single-cell transcriptomic profiling of the adult mouse spinal cord to gain insights into the organizational logic of the spinal cord. Our results reveal distinct spatial and laminar distributions of neuronal subtypes, including axial level and sex-specific differences. Many neuronal subtypes exhibit lamina-specific somat

Continue reading
Health & Medicine

Acute degradation of Pumilio proteins reveals a biphasic posttranscriptional regulatory hierarchy in embryonic stem cell fate decision.

Posttranscriptional regulation is critical for mammalian embryogenesis yet has been underexplored. We previously showed that RNA-binding Pumilio proteins (Pum1/2) are essential for early mouse embryogenesis and embryonic stem cell (ESC) functions. Here, using acute protein degradation systems combined with time-resolved RNA sequencing and enhanced crosslinking and immunoprecipitation, we delineate a two-phase regulatory hierarchy modulated by Pum1/2 in mouse ESCs. The first phase, occurring with

Continue reading
Health & Medicine

Elastic interactions of mechanically polarizable cells.

Cells mechanically interact through the deformations they generate in their surrounding extracellular matrix. We present an analytical theory of the elastic interactions between cells that actively adapt their forces in response to local deformations of their environment. Cells are represented as localized contractile force generators, modeled as polarizable point force dipoles, whose adaptive forces are determined self-consistently with those of surrounding cells. Analysis of the associated ela

Continue reading
Health & Medicine

ChREBP drives diabetic kidney disease, and its inhibition confers renal protection.

Chronic kidney disease (CKD) represents a major medical burden. Diabetic kidney disease (DKD) is a leading cause of CKD, but intracellular pathways that can be pharmacologically targeted are poorly defined. Using transcriptome screening of DKD model mice we found that a carbohydrate-responsive element-binding protein (ChREBP)-dependent transcriptional cascade is markedly up-regulated in diabetic kidneys. Genetic ablation of ChREBP in diabetic mice ameliorated DKD, establishing ChREBP as a potent

Continue reading